Pharming announces the launch of an offering of approximately €125 million senior unsecured convertible bonds due 2025
Highlights • Replaces and repays the loan facility with Orbimed • Accelerates expansion of production and commercial capability, including the new territories reacquired from Sobi • Allows Pharming to extend its debt maturity profile through the period of development of its existing pipeline
Leiden, The Netherlands, 14 January 2020: Pharming Group N.V. (“Pharming” or the “Company”) (Euronext Amsterdam: PHARM) announces today the launch of an offering (the “Offering”) of approximately €125 million of senior unsecured convertible bonds due 2025 (the “Bonds”). The net proceeds of the issue of the Bonds will be used to redeem the approximately US$ 56 million loan with Orbimed Advisors in full, thereby reducing the Company’s financing costs and extending its debt maturity through the period to approval of most of the Company’s existing pipeline. The balance of the net proceeds will be used to support capital expenditure in relation to the expansion of the commercialisation and manufacturing infrastructure of the Company, and serve as funding for the launch of Pharming’s recently acquired Leniolisib product and for additional acquisitions/inlicensing opportunities.